ReGen Therapeutics said that in in-vitro studies Colostrinin has been shown to prevent the aggregation of beta-amyloid and reduce it’s toxicity to cells. Colostrinin has also been shown to protect cells from oxidative stress another of the pathologies implicated in Alzheimer’s disease. In in-vivo studies Colostrinin has been shown to improve memory performance of aged rats in the Morris water maze test.
The approval now triggers a $50,000 payment to ReGen. Eczacibasi has placed an order with ReGen for a launch stock of blistered tablets for which ReGen is expected to receive a fee for the active ingredient component. These will be packaged locally by Eczacibasi under the brand-name ‘Dyna’ with product launch intended in May.
The announcement comes only a week after ReGen reported that Colostrinin is expected to be launched in India during the second quarter of 2010.